OTCPK:ELTP (USA) Also trade in: Germany

Elite Pharmaceuticals Inc

$ 0.06 0 (1.8%)
Volume: 98,780 Avg Vol (1m): 773,259
Market Cap $: 49.33 Mil Enterprise Value $: 64.07 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -0.1
Net Current Asset Value -0.02
Tangible Book -0.01
Projected FCF -0.08
Median P/S Value 0.1
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.57
Cash-To-Debt range over the past 10 years
Min: 0.08, Med: 1.8, Max: 10000
Current: 0.57
0.08
10000
Equity-to-Asset 0.47
Equity-to-Asset range over the past 10 years
Min: -3.34, Med: 0.54, Max: 0.9
Current: 0.47
-3.34
0.9
Debt-to-Equity 0.35
Debt-to-Equity range over the past 10 years
Min: -0.46, Med: 0.33, Max: 1.13
Current: 0.35
-0.46
1.13
Debt-to-EBITDA -0.53
Debt-to-EBITDA range over the past 10 years
Min: -1.7, Med: 0, Max: 13.04
Current: -0.53
-1.7
13.04
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -7.27
DISTRESS
GREY
SAFE
Beneish M-Score -2.13
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -149.01%
WACC 7.05%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -120.99
Operating Margin range over the past 10 years
Min: -329.15, Med: -78.72, Max: -20.77
Current: -120.99
-329.15
-20.77
Net Margin % -122.61
Net Margin range over the past 10 years
Min: -896.78, Med: -85.92, Max: 104.11
Current: -122.61
-896.78
104.11
ROE % -134.63
ROE range over the past 10 years
Min: -134.63, Med: -39.39, Max: -16.64
Current: -134.63
-134.63
-16.64
ROA % -33.75
ROA range over the past 10 years
Min: -232.83, Med: -22.42, Max: 20.79
Current: -33.75
-232.83
20.79
ROC (Joel Greenblatt) % -91.24
ROC (Joel Greenblatt) range over the past 10 years
Min: -830.35, Med: -58.26, Max: 90.2
Current: -91.24
-830.35
90.2
3-Year Total Revenue Growth Rate -15.40
3-Year Revenue Growth Rate range over the past 10 years
Min: -49.8, Med: -2.4, Max: 297.9
Current: -22
-49.8
297.9

» ELTP's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with OTCPK:ELTP

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers    NAICS : 325412    SIC : 2834
Compare HKSE:00897 TSXV:LG OSL:VISTIN OTCPK:CLSH NAS:BPTH XSAT:EQL DHA:AFCAGRO NAS:TLGT XCNQ:GLH WAR:MPH XCNQ:EPIC XCNQ:WRLD.U LSE:DNL XKLS:5278 XCNQ:EXM XCNQ:MPXI OTCPK:EXDI XCNQ:BIO XCNQ:ISOL XKRX:900120
Traded in other countries ETF.Germany
Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a US-based specialty pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company focuses on developing pain management products; manufacturing of a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; development of additional generic pharmaceutical products; development of the other products in its pipeline including the products with its partners; and commercialization of new products. The company operates through two segments namely Abbreviated New Drug Applications and New Drug Applications.

Ratios

Current vs industry vs history
PS Ratio 6.00
PS Ratio range over the past 10 years
Min: 0.47, Med: 10, Max: 74.44
Current: 6
0.47
74.44
EV-to-EBIT -7.19
EV-to-EBIT range over the past 10 years
Min: -556.1, Med: -2, Max: 209.6
Current: -7.19
-556.1
209.6
EV-to-EBITDA -8.53
EV-to-EBITDA range over the past 10 years
Min: -129.3, Med: -1.9, Max: 829.9
Current: -8.53
-129.3
829.9
EV-to-Revenue 8.46
EV-to-Revenue range over the past 10 years
Min: 1.3, Med: 11, Max: 76.9
Current: 8.46
1.3
76.9
Current Ratio 1.28
Current Ratio range over the past 10 years
Min: 0.33, Med: 2.68, Max: 19.21
Current: 1.28
0.33
19.21
Quick Ratio 0.63
Quick Ratio range over the past 10 years
Min: 0.22, Med: 1.98, Max: 19.21
Current: 0.63
0.22
19.21
Days Inventory 345.23
Days Inventory range over the past 10 years
Min: 131.1, Med: 250.42, Max: 588.1
Current: 345.23
131.1
588.1
Days Sales Outstanding 63.75
Days Sales Outstanding range over the past 10 years
Min: 33.08, Med: 53.51, Max: 105.24
Current: 63.75
33.08
105.24
Days Payable 106.76
Days Payable range over the past 10 years
Min: 64.98, Med: 190.64, Max: 1602.18
Current: 106.76
64.98
1602.18

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -4.70
3-Year Share Buyback Rate range over the past 10 years
Min: -117.9, Med: -19.15, Max: -4.7
Current: -4.7
-117.9
-4.7

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.60
Price-to-Median-PS-Value range over the past 10 years
Min: 0.18, Med: 2.11, Max: 1113
Current: 0.6
0.18
1113
Earnings Yield (Joel Greenblatt) % -13.91
Earnings Yield (Greenblatt) range over the past 10 years
Min: -254.5, Med: -10.8, Max: 73
Current: -13.91
-254.5
73

More Statistics

Revenue (TTM) (Mil) $ 7.57
EPS (TTM) $ -0.01
Beta 0.79
Volatility % 62.81
52-Week Range $ 0.03 - 0.13
Shares Outstanding (Mil) 828.39

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y